HEMOPROVE is an Open-label One Stage Phase II study sponsored by AP-HP.
The investigator hypothesis is that the treatment by Voxelotor (GBT440) will improve intra vascular hemolysis and will increase the total mass of hemoglobin with beneficial effects on organ function. The primary objective of the study is to evaluate the biological activity of Voxelotor on the reduction of intra vascular hemolysis measured by the biomarkers developed by Innovhem.
A new stage in Innovhem’s commitment to fight against Sickle Cell Disease
For more information https://clinicaltrials.gov/study/NCT05199766?cond=scd
